Abstract
The Breast Cancer Site Group (BCSG) of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) has conducted a wide variety of clinical trials focussing on large phase III trials of adjuvant chemotherapy, adjuvant hormonal therapy, and optimal delivery of adjuvant radiation therapy. The Group has also fostered, together with the NCIC CTG Investigational New Drug (IND) Program, a series of phase II and phase I/II studies which will be carried through if possible, into the phase III setting.
Highlights
The Breast Cancer Site Group (BCSG) of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) conducts clinical trials spanning a spectrum of research designs
The Investigational New Drug (IND) programme, chaired and co-chaired by Drs Elizabeth Eisenhauer and Lesley Seymour, interfaces with the BCSG to carry out phase II trials with a variety of new agents
The BCSG strategy is to test new agents that may be suitable for movement forward into larger phase III randomized trials either in metastatic disease or, in the adjuvant setting
Summary
It is the philosophy of the Group that large trials of adjuvant therapy are most important in terms of translating the maximum clinical benefit to the greatest number of patients with breast cancer. A phase I/II study conducted in patients with metastatic disease, MA.15 explored the optimal doses of the combination of taxotere and epirubicin with and without the use of colonystimulating factor.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
